MPR delivers practical, up-to-date drug information to healthcare professionals. Using the expertise gained from 25 years of providing point-of-care drug tools, MPR has now created a drug review course exclusively for See below for a list of each quarter's courses. Click here to visit MPR's website.

Latest Courses

Clinical Review

New-Drug Review from MPR (April 2014)

1.00 Credits

MPR Drug News

Updated Administration Information for Linzess

The FDA has approved a sNDA for Linzess (linaclotide; Actavis and Ironwood) to allow the capsule contents to be sprinkled in applesauce or water for adults with swallowing difficulties. Also, the FDA has approved additional instructions for patients with nasogastric or gastric feeding tubes.

FDA Approves First Seasonal Flu Vaccine with Adjuvant

The FDA has approved Fluad (influenza vaccine, adjuvanted; Seqirus) for the prevention of seasonal influenza in patients 65 years and older.

Review Questions Benefits of Common ADHD Med

Findings from a new Cochrane Review caution clinicians to weigh the benefits and risks more carefully when prescribing methylphenidate.

Results for Lyrica in Post-Traumatic Peripheral Neuropathic Pain Announced

Pfizer announced that a Phase 3 study evaluating the efficacy and safety of Lyrica (pregabalin) Capsules CV in adults with chronic post-traumatic peripheral neuropathic pain did not meet its primary efficacy endpoint.

Study Explores the Role of Aspirin in Cancer Prevention

Researchers may have identified a new mechanism for aspirin in cancer prevention, according to findings from a study published in Cancer Epidemiology, Biomarkers, and Prevention.